RxDoctor Payments Data

Lisa Bethel, NP

Family · Langhorne, PANPI 1265018030

Payments from drug & device makers

$1,112in general payments, 2019–2025

Across 31 payments — averaging $35.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$512
  • Scilex Pharmaceuticals Inc.$125
  • Johnson & Johnson$117
  • AbbVie$88
  • Sumitomo Pharma America, Inc.$54
  • Exact Sciences$46
  • plus $171 from 6 others

What the payments were for

  • Food & beverage$1,112100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,112 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$184,147
Medicare patients
334
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$54,976
JanuviaSitagliptin Phosphate52$50,632
XifaxanRifaximin17$27,464
JardianceEmpagliflozin39$23,869
OzempicSemaglutide19$22,674
FarxigaDapagliflozin Propanediol23$16,397
GemtesaVibegron55$14,973
Breo ElliptaFluticasone/Vilanterol21$13,518
XareltoRivaroxaban36$12,996
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,410
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$3,846
Diclofenac Sodium30$3,782
Levothyroxine Sodium265$3,437
Xtampza ErOxycodone Myristate15$3,197
Gabapentin166$3,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$54,97689 claims
Novo NordiskOzempic$512$22,67419 claims
AstraZenecaFarxiga$20$16,39723 claims
Sumitomo Pharma America, Inc.Gemtesa$54$14,97355 claims
Johnson & JohnsonXarelto$117$12,99636 claims
AbbVieSynthroid$88$94522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →